Product Description: Trachelogenin ((-)-Trachelogenin) is an HCV entry inhibitor without genotype specificity, and with low cytotoxicity. Trachelogenin inhibits HCVcc infection and HCVpp cell entry in a dose-dependent manner with an IC50 of 0.325 and 0.259 μg/mL in HCVcc and HCVpp models, respectively. Trachelogenin exhibits effective antiviral, anti-inflammatory and analgesic effects[1].
Applications: COVID-19-anti-virus
Formula: C21H24O7
References: [1]Xi-Jing Qian, et al. Trachelogenin, a novel inhibitor of hepatitis C virus entry through CD81. J Gen Virol. 2016 May;97(5):1134-1144.
CAS Number: 34209-69-3
Molecular Weight: 388.41
Compound Purity: 99.56
Research Area: Infection; Inflammation/Immunology; Neurological Disease
Solubility: DMSO : 100 mg/mL (ultrasonic)
Target: HCV